pregnancy specific beta-1-glycoprotein 7Genealiases: PS-beta-G-7 · PSBG-7 · PSGGA
Q-omics provides the consensus-scored PSG7 profile across patient tissues and cancer cell-line models. PSG7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSG7 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, PSG7 RNA expression shows 9,520 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where PSG7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSG7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSG7 survival associations across molecular data types. PSG7 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSG7 RNA expression–survival associations across cancer types. High PSG7 expression shows unfavorable associations in KIRC, SKCM, TGCT and THCA, but favorable associations in GBM and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSG7 RNA expression.
This table summarizes PSG7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PSG7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSG7 shows higher tumor expression in THCA, CHOL, KICH and LIHC. The THCA box plot shows higher PSG7 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .010).
This table shows molecular features associated with PSG7 in patient tissues and cancer cell lines. In patient samples, PSG7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSG7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
